重藥控股(000950.SZ):化醫集團轉讓健康產業公司49%股權已完成過户
格隆匯1月16日丨重藥控股(000950.SZ)公佈,2020年1月16日,公司收到健康產業公司通知,化醫集團將其所持有的健康產業公司22%股權轉讓給中國通用及將其所持有的健康產業公司27%股權轉讓給中國醫藥事項已辦理完畢股權過户相關工商變更登記手續。
此次股權轉讓實施完畢之後,化醫集團持有健康產業公司51%股權,中國通用及中國醫藥將合計持有健康產業公司49%股權,其中:中國通用持有健康產業公司22%股權、中國醫藥持有健康產業公司27%股權。重藥控股的控股股東仍為健康產業公司,重藥控股的實際控制人仍為重慶市國有資產監督管理委員會,重藥控股的控制權不會發生變更。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.